Open Label Safety Study in Acute Treatment of Migraine

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Migraine, With or Without Aura Clinical Trial

Official title:
A Multicenter, Open Label Long-Term Safety Study of BHV-3000 in the Acute Treatment of Migraine

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate safety and tolerability of BHV-3000 (rimegepant).

n/a

See also
Status	Clinical Trial	Phase
Completed	`NCT02848326` - Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention	Phase 2/Phase 3
Completed	`NCT02873221` - An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine	Phase 3
Completed	`NCT03237845` - Safety and Efficacy in Adult Subjects With Acute Migraines	Phase 3
Completed	`NCT02828020` - Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine	Phase 3
Completed	`NCT03235479` - Safety and Efficacy Study in Adult Subjects With Acute Migraines	Phase 3
Completed	`NCT03461757` - Trial in Adult Subjects With Acute Migraines	Phase 3
Completed	`NCT02867709` - Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine	Phase 3